Phase II trial of pembrolizumab and epacadostat in recurrent clear cell carcinoma of the ovary: An NRG oncology study GY016

<i>ARID1A</i> Mutations in Endometriosis-Associated Ovarian Carcinomas

Kimberly C. Wiegand, Sohrab P. Shah, Osama M. Al‐Agha et al. · New England Journal of Medicine · 2010 · 1.7K citations · Full text

Medicine, Genetics, Oncology +17

Safety and Antitumor Activity of Anti–PD-1 Antibody, Nivolumab, in Patients With Platinum-Resistant Ovarian Cancer

Junzo Hamanishi, Masaki Mandai, Takafumi Ikeda et al. · Journal of Clinical Oncology · 2015 · 1.2K citations

Medicine, Oncology, Pharmacology +17

Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study

Georgina V. Long, Reinhard Dummer, Omid Hamid et al. · The Lancet Oncology · 2019 · 944 citations

Medicine, Oncology, Pharmacotherapy +15

Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study

Ursula A. Matulonis, Ronnie Shapira‐Frommer, Alessandro D. Santin et al. · Annals of Oncology · 2019 · 840 citations · Full text

Medicine, Oncology, Pharmacology +15

ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade

Jianfeng Shen, Zhenlin Ju, Zhao Wei et al. · Nature Medicine · 2018 · 571 citations

Medicine, Immunology, Oncology +16